Table 1.
Odd ratios (with confidence intervals) and heterogeneity for each of the cancer risks analysed
| Outcome | OR | 95% CI | I2 | Degree of heterogeneity |
|---|---|---|---|---|
| The risk of IOC between OI and CT group (based on case-control study) | 1.09 | 0.88-1.35 | 54.9% | Moderate |
| The risk of BOT between OI and CT group (based on case-control study) | 1.90 | 0.89-4.09 | 73.4% | Moderate |
| The risk of IOC between OI and CT group (based on cohort study) | 1.11 | 0.91-1.35 | 21.8% | Low |
| The risk of BOT between OI and CT group (based on cohort study) | 1.34 | 0.97-1.83 | 50.5% | Moderate |
| The risk of IOC between OI and CT group (in multiparous women) | 0.83 | 0.65-1.05 | 21.3% | Low |
| The risk of BOT between OI and CT group (in nulliparous women) | 1.17 | 0.55-2.48 | 73.5% | Moderate |
| The risk of IOC between OI and CT group (in nulliparous women) | 1.55 | 0.94-2.57 | 69.5% | Moderate |
| The risk of BOT between OI and CT group (in nulliparous women) | 1.49 | 1.03-2.15 | 0% | Low |
| The risk of IOC between the nulliparous and multiparous women (with ovulation induction treatment) | 3.35 | 2.10-5.34 | 52.2% | Moderate |
| The risk of BOT between the nulliparous and multiparous women (with ovulation induction treatment) | 2.58 | 1.76-3.79 | 0% | Low |
| The risk of IOC between OI and CT group (less than 3 ovulation induction cycles) | 1.05 | 0.72-1.52 | 42.9% | Low |
| The risk of IOC between OI and CT group (more than 3 ovulation induction cycles) | 0.98 | 0.79-1.22 | 0% | Low |
| The risk of IOC between OI and CT group (less than 6 ovulation induction cycles) | 0.85 | 0.64-1.12 | 0% | Low |
| The risk of IOC between OI and CT group (more than 6 ovulation induction cycles) | 0.88 | 0.59-1.31 | 0% | Low |
| The risk of IOC between OI and CT group (less than 12 ovulation induction cycles) | 0.87 | 0.69-1.10 | 0% | Low |
| The risk of IOC between OI and CT group (more than 12 ovulation induction cycles) | 0.78 | 0.49-1.22 | 0% | Low |
| The risk of IOC between CC and CT group | 1.01 | 0.88-1.17 | 0% | Low |
| The risk of BOT between CC and CT group | 1.32 | 0.79-2.21 | 72.6% | Moderate |
| The risk of IOC between GDT and CT group | 1.08 | 0.80-1.44 | 0% | Low |
| The risk of BOT between GDT and CT group | 1.73 | 0.88-1.93 | 54.1% | Moderate |
| The risk of IOC between HCG and CT group | 1.10 | 0.71-1.71 | 34.7%, | Low |
| The risk of BOT between HCG and CT group | 1.28 | 0.71-2.31 | 56% | Moderate |
| The risk of IOC between HMG and CT group | 1.07 | 0.44-2.57 | 71.6% | Moderate |
| The risk of BOT between HMG and CT group | 5.31 | 0.73-38.72 | 83.3% | High |
| The risk of IOC between GnRH-a and CT group | 0.49 | 0.07-3.66 | 71.9% | Moderate |
CC Clomiphene citrate, GDT Gonadotrophin, GnRH-a Gonadotropin-releasing hormone analogues, HCG human menopausal gonadotropin, HMG human chorionic gonadotropin, IOC invasive ovarian cancer, BOT borderline ovarian tumor, OI ovulation induction group, CT control group, OR odds ratio, 95%CI 95% confidence interval